NCT01174979暂停3 期
Double Blind, Placebo-controlled, Randomized Clinical Trial to Evaluate the Efficacy and Safety of a Transtympanic Treatment of Tinnitus With Caroverine
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 暂停
- 发起方
- Phafag AG
- 入组人数
- 170
- 试验地点
- 1
- 主要终点
- to investigate the efficacy of Caroverin in transtympanic treatment of patients with tinnitus measured by a visual analogue scale.
研究概览
简要总结
This trial is a randomized, double blind, placebo controlled study on patients suffering from inner ear diseases with tinnitus as a principal symptom.
The study will investigate the transtympanic treatment with a 1,5 % caroverine solution.
Each patient will undergo treatment for 2 cycles of 48 hours each.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Men or women aged at least eighteen
- •Written consent to take part in the study after receiving information from the trial physician
- •One of the following illnesses:
- •Decompensated tinnitus
- •Sudden hearing loss
- •Morbus Menière
- •Blast injury
- •Presbyacusis with Tinnitus
- •Chron. Otitis media
排除标准
- •Patients who are not able to give their consent (e.g. dementia, coma, mental disability,...)
- •Women of childbearing age who are not using adequate contraception or who are (or plan to become) pregnant (a pregnancy test must be carried out by a doctor once a month in Austria) or are lactating
- •If there are solid reasons to doubt that the patient would be willing and able to cooperate
- •Known intolerance of/hypersensitivity to caroverine
- •Subjects who have taken part in another clinical trial within the 30 days preceding the start of this study or during this study
- •Pulse-synchronous tinnitus
- •Tinnitus caused by malposition of the jaw bone (bruxism)
- •Eardrum perforation
- •Subjects who have previously had a barotraumas, diving accidents or decompression sickness
- •Retrocochlear hearing disorder
- •Patients who have previously had a fracture of the petrous bone
- •Subjects suffering from acute or chronic accompanying conditions which severely impede their general health (NYHA stage IV, cancer, HIV etc.)
- •Accompanying conditions that according to the current state of scientific knowledge could affect the parameters used in this study to such an extent as to make it impossible to perform an objective assessment of those parameters, particularly ear conditions, including any conditions affecting the other ear or conditions like HI NYHA stage IV, cancer, HIV, Wallenberg Syndrome, massive Hypotension, Glaucoma.)
- •Accompanying medication that according to the current state of scientific knowledge are likely to affect the measurement techniques used in this study or the results obtained (cytostatics, aminoglycoside antibiotics, loop diuretics (furosemide, etacrynic acid), psycho pharmaceuticals, muscle relaxants, benzodiazepines, salicylates, quinine, cortisone and/or caroverine within the three days preceding the start of the study)
- •Drug treatment for tinnitus or sudden hearing loss (i.v. and oral) within seven days preceding the start of the study where the total duration of the course is less than four weeks
- •Diseases or conditions that may be associated with an altered perception or processing of stimuli, e.g. mental illness
研究组 & 干预措施
Caroverin
Experimental
干预措施: Caroverin (Drug)
Placebo
Placebo Comparator
干预措施: Caroverin (Drug)
结局指标
主要结局
to investigate the efficacy of Caroverin in transtympanic treatment of patients with tinnitus measured by a visual analogue scale.
时间窗: treatment takes 5 days, follow up examination 4 weeks after
次要结局
- to investigate the time from the start of treatment to an improvement in tinnitus(treatment takes 5 days, follow up examination 4 weeks after)
- to investigate the efficacy of Caroverin depending the origin of tinnitus(treatment takes 5 days, follow up examination 4 weeks after)
- to investigate the safety of Caroverin treatment(treatment takes 5 days, follow up examination 4 weeks after)
- to investigate the impact of Caroverin treatment of quality of life(treatment takes 5 days, follow up examination 4 weeks after)
研究者
研究点 (1)
Loading locations...
相似试验
Unknown
4 期
Smoking Cessation Program in the Preadmission ClinicSmokingNCT00937508University Health Network, Toronto290
已完成
2 期
Efficacy of Rifaximin in Preventing CampylobacteriosisDiarrheaEnteric CampylobacteriosisDysenteryNCT02280044Johns Hopkins Bloomberg School of Public Health30
Unknown
3 期
Study of Tyroserleutide for Injection in Hepatocellular Carcinoma (HCC) PatientsHepatocellular,CarcinomaNCT01489566Shenzhen Kangzhe Pharmaceutical Co., Ltd.300
Unknown
不适用
Baclofen/Diazepam Supps for Treatment of Pelvic Floor MyalgiaPelvic Floor DyssynergiaNCT03427216Dr. John A. Thiel Medical Professional Corporation60
Unknown
3 期
Expanding Phase III Study of Tyroserleutide for InjectionHepatocellular CarcinomaNCT03516448Shenzhen Kangzhe Pharmaceutical Co., Ltd.352